Results. - Sixteen patients were included (9 women and 7 men). They had recurrent anterior uveitis (n=10), recurrent scleritis (n=5) and intermediate uveitis. Opthalmological involvement was neither severe nor complicated. All patients combined, the annual relapse ratio (ARR) decreased from 1.8 (0.8-3.5) to 0.3 (0-1.6), (P=0.06). Colchicine was considered effective in three of 10 analyzable patients. In only one patient, treatment was stopped for adverse effects after six weeks. Conclusion. - In view of the interesting benefit-risk ratio of colchicine, it seems appropriate to focus on this molecule in non-granulomatous anterior uveitis and non-severe recurrent scleritis. (c) 2022 Socie acute accent te acute accent Nationale Franc , aise de Me acute accent decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.

Rogier, T; Auvens, C; Thibault, T; Mouries-Martin, S; Muller, G; El Hssaini, N; Turcu, A; Besancenot, JF; Bielefeld, P; Devilliers, H

Rogier, T (通讯作者)，CHU Dijon, Serv medecine interne & Malad Syst, 14, rue Paul Gaffarel, F-21000 Dijon, France.

REVUE DE MEDECINE INTERNE, 2022; 43 (11): 640